Marc Coucke, Belgian billionaire with an estimated fortune of over 1.25 billion euros, is the epitome of successful entrepreneurship. From the founding of Omega Pharma to his varied investments in sport, leisure and healthcare, Coucke continues to make his mark on the Belgian and international business landscape in 2024.
Rudi Mariën, a Belgian pharmacist and entrepreneur, has played a decisive role in the development of biotechnology in Belgium. Founder of Innogenetics and a key investor in numerous biotech companies, Mariën has accumulated assets of over 200 million euros. His commitment to innovation and technological development, notably through projects such as Tech Lane Ghent, continues to inspire the biotech sector worldwide.
Marc Reynders, alongside his brothers Paul and Jacques, successfully manages Reynders Label Printing, a Belgian family business specializing in self-adhesive label printing. Founded in 1956, the company is now a major player in the sector, with sales in excess of 180 million euros and an international presence. With assets valued at 244 million euros, the Reynders family ranks among the 110 richest families in Belgium, demonstrating sustained profitability and growth.
The Declerck-Allegaert family, founders of Klinisch Laboratorium Declerck, have transformed a local business into a major player in healthcare services in Flanders. With advanced technologies and rapid medical results, this laboratory gained notoriety, culminating in its acquisition by Australian giant Sonic Healthcare in 2015. Today, with assets of over 37 million euros, the family continues to stand out for its commitment to the community and quality of care.
The Janssen family, one of Belgium's most influential dynasties, has positioned itself at the heart of the banking, industrial and pharmaceutical sectors. With assets estimated at over 3 billion euros, their legacy is marked by strategic alliances, notably with the Solvay group and UCB, and by rigorous management of their assets. From Daniel Janssen to Charles-Antoine Janssen, each generation has strengthened the family's grip on the Belgian economy. Discover how this family has combined tradition, innovation and strategy to become one of Belgium's wealthiest.
Dr. Paul Janssen, founder of Janssen Pharmaceutica, is one of the most influential figures in the Belgian pharmaceutical industry. With a legacy estimated at over 300 million euros, Janssen revolutionized medicine with innovative medicines, while remaining a central figure in the company after its takeover by Johnson & Johnson. In addition to his medical contributions, he left a significant cultural imprint, with a unique collection of pre-Columbian art. Discover how this visionary built a pharmaceutical empire while influencing Belgian art and economics.
Founded in 1987 by Dirk Putteman, Belchim Crop Protection has become a major player in the distribution of crop protection products in Europe. Despite financial challenges and the loss of its founder, the company continues to prosper thanks to strategic partnerships and a strong international presence. The Putteman family, with an estimated fortune of over 57 million euros, embodies innovation and resilience in the agricultural sector. Discover how their heritage and strategy have shaped a world-renowned company.
Gino De Raedt and Frederica Verheyden have built a financial empire estimated at over 1.7 billion euros, from a simple medical laboratory in 1978 to major players in European biotechnology. Their journey, marked by strategic acquisitions and a spectacular merger with Biogroup, illustrates an exceptional entrepreneurial vision. With record dividends and diversified investments in real estate and private equity, the De Raedt-Verheyden couple have become one of Belgium's largest fortunes, while preparing for the future with their daughter Ann. Their story embodies the perfect blend of scientific innovation and financial genius.
Immerse yourself in the world of Patrick Solvay, heir to a chemical and financial empire valued at 151 million euros. From major influence in the global chemical industry to ownership of a prestigious golf course, discover how this great-grandson of Alfred Solvay perpetuates and diversifies the legacy of one of Belgium's most influential families.
Serge Goblet, a Belgian investor with an estimated fortune of 159 million euros, has built a diversified empire combining commerce, real estate and biotechnology. His flagship investment, Celyad Oncology SA, develops innovative CAR-T cancer therapies. Goblet illustrates the successful alliance between entrepreneurial spirit and medical innovation, contributing to therapeutic advances while consolidating a portfolio of international assets in various sectors.
